RK-33

Cas No.:	1070773-09-9
Chemical Name:	RX33, RX 33
Synonyms:	RX33, RX 33
SMILES:	C1=C(OC)C=CC(CN2C3N=CN=C4N(CC5=CC=C(OC)C=C5)C(=O)N=C4C=3N=C2)=C1
Formula:	C23H20N6O3
M.Wt:	428.16
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
In Vivo:	There is more cell death (pyknotic or condensed nuclei) admixed with fibrin and interstitial edema in the tumors from mice from the combination RK-33 and radiation group compared to the control or single treatment groups. The treatment combination of RK-33 and radiation has an advantage in reducing tumor proliferation[1]. In the mice treated with RK-33-PLGA, RK-33 can be detected in the plasma (34 μg/mL) and liver (28 μg/g), but not lungs[2].
In Vitro:	RK-33 shows inhibition of many kinds of cancer cells with IC50 of 3-6 µM, while PC3 is much less sensitive to RK-33 (IC50 >12 µM). RK-33 treatment causes a significant accumulation in the G1 phase for DU145 and LNCaP, although treatment with RK-33 causes only a moderate accumulation of the G1 phase for 22Rv1, and the treated cells have significantly reduced G2 phase. RK-33 treatment also causes 12 moderate G1 accumulation in 22Rv1[1]. RK-33-loaded NPs demonstrate cytotoxicity to MCF-7 cells in a dose-dependent manner, while equivalent doses of empty NPs have no killing effect. The IC50 value of 5% RK-33 loaded NPs is 49 μg/mL, and the IC50 value of 10% RK-33 loaded NPs is 25 μg/mL[2].